Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
source https://www.nytimes.com/2021/10/20/health/covid-molnupiravir-gates-foundation.html
0 Comments